secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001493152-26-007287
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine completes last patient last visit in Phase 3 trial of LPCN 1154 for PPD
--------------------------------------------------------------------------------

- Last patient completed final visit in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression.
- Trial enrolled 90 patients with severe PPD (average baseline HAM-D 28.3); positive safety profile with no discontinuations.
- Company expects Phase 3 data to support 505(b)(2) NDA submission for LPCN 1154 in 2026.
- Preliminary cash and equivalents ~$19M as of Jan 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226007287/0001493152-26-007287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226007287/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer